Evommune Targets $5B Skin‑Disorder Sales, Aims to Transform Chronic Inflammatory Therapy
Evommune’s $5 B skin‑disorder sales forecast and focus on chronic inflammation make it a biotech disruptor—high risk, high reward for savvy investors.
3 minutes to read